Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

Aberrant activation of Janus kinase 2 (JAK2) caused by somatic mutation of JAK2 (JAK2V617F) or the thrombopoietin receptor (MPLW515L) plays an essential role in the pathogenesis of myeloproliferative neoplasms (MPNs), suggesting that inhibition of aberrant JAK2 activation would have a therapeutic be...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaya, Y, Shide, K, Niwa, T, Homan, J, Sugahara, S, Horio, T, Kuramoto, K, Kotera, T, Shibayama, H, Hori, K, Naito, H, Shimoda, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255248/
https://www.ncbi.nlm.nih.gov/pubmed/22829185
http://dx.doi.org/10.1038/bcj.2011.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255248/
https://www.ncbi.nlm.nih.gov/pubmed/22829185
http://dx.doi.org/10.1038/bcj.2011.29

Ejemplares similares